BIONIC EYE TRIAL RESULTS SHOW SUBSTANTIAL VISION IMPROVEMENTS OVER TWO AND A HALF YEARS Blind participants with retinitis pigmentosa able to locate doorways, avoid obstacles
SEGMENT
Filmed in Melbourne and Sydney | February 2025
Released on Retinitis Pigmentosa Awareness Month
INTERVIEWED
Professor James Fallon,
Chief Technology Officer Bionics Institute &
Head of the Medical Bionics Department, University of Melbourne
Associate Professor Penelope Allen,
Head of Bionic Eye Project & Principal Investigator,
Centre for Eye Research Australia (CERA) &
Vitreoretinal Surgeon,
Royal Victorian Eye and Ear Hospital
Dr Ash Attia
Chief Executive Officer & Managing Director
Bionic Vision Technologies
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Detailed outcomes from the trial, led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, were published in Ophthalmology Science.
The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
Retinitis pigmentosa is an inherited retinal disease which affects about two million people worldwide and is one of the leading causes of vision loss in working-age people.
The bionic eye comprises an electrode array, designed by the Bionics Institute and the Centre for Eye Research Australia, that is surgically implanted behind the eye. The electrode receives signals from a video camera mounted on glasses, which stimulate the patient’s retina.
Credit: Retinitis pigmentosa fact sheet from Retina Australia
-
The quest to create an Australian framework for a Palliative Care Pharmacist
Helen Stone is the State and Territory Manager SA & NT for the Pharmaceutical Society Australia. Her professional interests include palliative care, pharmacist professional services, mental health, leadership, and management.
She has recently led teams of pharmacists in innovative pharmacy practice models including in aged care, GP practice, palliative care and dementia support. This has contributed to the body of evidence for sustainable funding for embedded pharmacist roles in primary care and aged care settings.
-
HEALTH CARE BRIEF: Myopia progression in children
Myopia progression in children – Incidence rates, prevalence, risks, symptoms and treatment options
-
Research, Mentorship and the PhD Experience
Pancreatic cancer remains one of the deadliest cancers, with survival rates below 10 per cent and treatments often as harsh as the disease itself.
Finding better ways to treat one of the deadliest cancers has become the focus of a University of Wollongong research team, where the relationship between a PhD supervisor and candidate has also played an important role in shaping the next generation of researchers.
